Nouress
NDC Package 76014-006-05
Package Information
Nouress is indicated for use as an additive to amino acids solutions to meet nutritional requirements of neonates (preterm and term infants less than one month of age) requiring total parenteral nutrition. Marketed by Avadel Legacy Pharmaceuticals, Llc, this product is identified by NDC 76014-006 and is authorized under FDA application NDA212535.
Identification & Billing
- RxCUI: 1667993 - cysteine HCl 0.5 GM in 10 ML (50 MG/ML) Injection
- RxCUI: 1667993 - 10 ML cysteine hydrochloride 50 MG/ML Injection
- RxCUI: 1667993 - cysteine HCl 0.5 GM per 10 ML Injection
- RxCUI: 2286589 - NOURESS 500 MG in 10 ML Injection
- RxCUI: 2286589 - 10 ML cysteine hydrochloride 50 MG/ML Injection [Nouress]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 76014 - Avadel Legacy Pharmaceuticals, Llc
- 76014-006 - Nouress
- 76014-006-05 - 5 VIAL, SINGLE-USE in 1 CARTON / 10 mL in 1 VIAL, SINGLE-USE (76014-006-33)
- 76014-006 - Nouress
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 76014-006-05 identifies a specific commercial package of 5 vial, single-use in 1 carton / 10 ml in 1 vial, single-use (76014-006-33) of Nouress, labeled by Avadel Legacy Pharmaceuticals, Llc. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Avadel Legacy Pharmaceuticals, Llc on April 01, 2020. The current certification is valid through December 31, 2021.
How is this Avadel Legacy Pharmaceuticals, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 76014000605. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.